News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

NVAMD risk tied to semaglutide no different from other antidiabetes medications
01 Nov 2026
byStephen Padilla
The risk of neovascular age-related macular degeneration (NVAMD) associated with the use of semaglutide is similar to that with other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or non-GLP-1 RAs among adults with type 2 diabetes (T2D), suggests a study.
01 Nov 2026

Weight loss lowers MACE, T2D risks in women, but weight regain reduces benefits
31 Oct 2026
byStephen Padilla
Healthy premenopausal women with overweight who lose weight through diet with or without aerobic or resistance exercise show a significant reduction in the risks of major adverse cardiovascular events (MACE) and type 2 diabetes (T2D). However, such risks have rebounded with weight regain.
31 Oct 2026






